Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors

American Journal of Clinical Pathology

Volumn 130, Issue 3, 2008, Pages 446-454

  Calatzis, Andreas ^a   Peetz, Dirk ^b   Haas, Sylvia ^c   Spannagl, Michael ^a   Rudin, Karin ^d   Wilmer, Marianne ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Research and Development   (Switzerland)

Author keywords

Anticoagulation monitoring; Direct thrombin inhibitors; Heparins; PiCT; Prothrombinase induced clotting time assay

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID; PROTHROMBIN A; RUSSELL VIPER VENOM FACTOR V ACTIVATOR; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; VIPER VENOM;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEVICE; DRUG MONITORING; HUMAN; HUMAN TISSUE; INCUBATION TIME; NORMAL HUMAN; PRIORITY JOURNAL; PROTHROMBINASE INDUCED CLOTTING TIME ASSAY; THROMBOCYTE POOR PLASMA;

BLOOD COAGULATION TESTS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES; SENSITIVITY AND SPECIFICITY; THROMBOPLASTIN;

EID: 51349132444     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/Q0G21Y26UR0UHQ1A     Document Type: Article

References (39)

1. Kher A, Samama MM. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost. 2005;3:473-481.
2. Iorio A. Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents. J Thromb Haemost. 2004;2:1055-1057.
3. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105:453-463.
4. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 suppl):64S-94S.
5. Heizmann M, Baerlocher GM, Steinmann F, et al. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res. 2002;106:179-181.
6. Chan DK, Ong B, Almafragy H, et al. Safety and low molecular weight heparin in older people in a hospital with ambulatory care. Arch Gerontol Geriatr. 2005;43:233-241.
7. Green B, Greenwood M, Saltissi D, et al. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol. 2005;59:281-290.
8. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med. 2003;31:1405-1409.
9. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-3116.
10. Siguret V, Pautas E, Gouin I. Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004. Curr Opin Pulm Med. 2004;10:366-370.
11. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119:104-109.
12. Reed SV, Haddon ME, Denson KW. An attempt to standardize the APTT for heparin monitoring, using the P.T. ISI/INR system of calibration: results of a 13 centre study. Thromb Res. 1994;74:515-522.
13. Eby C. Standardization of APTT reagents for heparin therapy monitoring: urgent or fading priority? Clin Chem. 1997;43:1105-1107.
14. Toulon P, Boutiére B, Horellou MH, et al. Monitoring heparin therapy using activated partial thromboplastin time: results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin. Thromb Haemost. 1998;80:104-108.
15. Kitchen S, Iampietro R, Woolley AM, et al. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost. 1999;82:1289-1293.
16. Depasse F, Gilbert M, Goret V, et al. Anti-Xa monitoring: inter-assay variability [letter]. Thromb Haemost. 2000;84:1122-1123.
17. Douketis JD, Kinnon K, Crowther MA. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery. Thromb Haemost. 2002;88:37-40.
18. ten Cate H, Lamping RJ, Henny CP, et al. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem. 1984;30:860-864.
19. Dignac M, Gabaig AM, Cambus JP, et al. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins. Nouv Rev Fr Hematol. 1994;35:545-549.
20. Bara L, Combe-Tamzali S, Conard J, et al. Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest). Haemostasis. 1987;17:127-133.
21. Harenberg J. Is laboratory monitoring of low-molecularweight heparin therapy necessary? Yes. J Thromb Haemost. 2004;2:547-550.
22. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost. 2004;2:551-554.
23. Shojania AM. More on: is laboratory monitoring of low-molecular-weight heparin necessary [letter]? J Thromb Haemost. 2004;2:2276-2277.
24. Bachmann F. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost. 2004;2:1005-1006.
25. Kearon C. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost. 2004;2:1006-1007.
26. Ray M, Carroll P, Smith I, et al. An attempt to standardize APTT reagents used to monitor heparin therapy. Blood Coagul Fibrinolysis. 1992;3:743-748.
27. Niles SD, Sutton RG, Ploessl J, et al. Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery. J Extra Corpor Technol. 1995;27:197-200.
28. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment: an evaluation of native blood and plasma assays. Thromb Haemost. 1994;72:685-692.
29. Walenga JM, Hoppensteadt D, Koza M, et al. Laboratory assays for the evaluation of recombinant hirudin. Haemostasis. 1991;21(suppl 1):49-63.
30. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost. 1996;22:197-202.
31. Calatzis A, Spannagl M, Gempeler-Messina P, et al. The prothrombinase-induced clotting test: a new technique for the monitoring of anticoagulants. Haemostasis. 2000;30(suppl 2):172-174.
32. Harenberg J, Giese C, Hagedorn A, et al. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost. 2007;33:503-507.
33. Fenyvesi T, Jörg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb. 2002;32:174-179.
34. Graff J, Picard-Willems B, Harder S. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther. 2007;45:237-243.
35. Tokunaga F, Nagasawa K, Tamura S, et al. The factor V-activating enzyme (RVV-V) from Russell's viper venom. J Biol Chem. 1988;263:17471-17481.
36. Dawes J, Pumphrey CW, McLaren KM, et al. The in vivo release of human platelet factor 4 by heparin. Thromb Res. 1982;27:65-76.
37. Lyon SG, Lasser EC, Stein R. Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect of antithrombin III concentration. Thromb Haemost. 1987;58:884-887.
38. Mouton C, Calderon J, Janvier G, et al. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine. Thromb Res. 2003;111:273-239.
39. Maddineni J, Hoppensteadt DA, Cornelli U, et al. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate. Clin Appl Thromb Hemost. 2007;13:52-64.